Year: 2019

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) (THE “SECURITIES ACT”) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES, THE UNITED KINGDOM, FRANCE AND ITALY) MAY BE RESTRICTED BY LAW.Bank Norwegian AS (publ) (the “Issuer”), is offering holders of its outstanding bonds outlined below (the “Bonds”) to tender for purchase by the Issuer for...

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) (THE “SECURITIES ACT”) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES, THE UNITED KINGDOM, FRANCE AND ITALY) MAY BE RESTRICTED BY LAW.Bank Norwegian AS (publ) (the “Issuer”), is offering holders of its outstanding bonds outlined below (the “Bonds”) to tender for purchase by the Issuer for...

 Company announcement, Helsinki, 5 December 2019 at 11.10 am (EET)Nexstim Plc: Health Canada Grants Nexstim NBT® Medical Device License for CanadaNexstim Plc (NXTMH:HEX, NXTMS:STO) announces that its NBT® System with SmartFocus® TMS technology has received a medical device license from Health Canada.The medical device license allows Nexstim to start marketing and commercial distribution of the NBT® system for the treatment of Major Depressive Disorder (MDD) in Canada.MDD is a recurrent and frequently chronic disorder with significant unmet clinical need: An estimated 10 per cent of Canadians use health services for mood and anxiety disorders annually1).  According to Statistics Canada, 1,330,510 Canadians over the age of 15 reported indicators for ‘Major depression episode’ in 2012.2)Stimulation of the brain through Transcranial Magnetic...

Yhtiötiedote, Helsinki, 5.12.2019 klo 11.10Nexstim Oyj: Kanadan terveysviranomainen on myöntänyt Nexstimin NBT®-laitteistolle lääkintälaitelisenssinNexstim Oyj (NXTMH:HEX, NXTMS:STO) ilmoittaa, että yhtiön kehittämä NBT® laitteisto on saanut lääkintälaitelisenssin Kanadan terveysviranomaiselta Health Canadalta.Myönnetty lääkintälaitelisenssi mahdollistaa Nexstimille NBT® -laitteiston myynnin ja markkinoinnin vakavan masennuksen (MDD) hoitoon Kanadassa.Vakava masennus on toistuva ja usein kroonistuva sairaus, jolla on selkeä tyydyttämätön hoitotarve: Arviolta 10 prosenttia kanadalaisista käyttää vuosittain terveyspalveluita mieliala- ja ahdistushäiriöiden hoitoon1). Statistics Canadan mukaan 1 330 510 yli 15 vuotiasta kanadalaisista raportoi vakavaan masennukseen liittyviä oireita vuonna 20122).Aivojen stimulointi kallon ulkopuolisella...

Företagsmeddelande, Helsingfors 5 december 2019 kl. 11.10 (EET)Nexstim Abp: Health Canada medicintekniska godkännande för Nexstim NBT® SystemNexstim Abp (NXTMH:HEX, NXTMS:STO) meddelar att dess NBT®-system med SmartFocus® TMS-teknik har godkänts som medicinteknisk produkt av den kanadensiska läkemedelsmyndigheten Health Canada.Tack vare godkännandet kan Nexstim inleda marknadsföring och kommersiell distribution av NBT®-systemet för behandling av egentlig depression (MDD) i Kanada.MDD är ett återkommande och ofta kroniskt tillstånd där de kliniska behoven i stor utsträckning inte är uppfyllda. I Kanada uppsöker uppskattningsvis 10 procent av befolkningen årligen hälso- och sjukvård på grund av affektiva störningar och ångeststörningar1).  Enligt statistikmyndigheten Statistics Canada rapporterade 1 330 510 över 15-åriga personer i Kanada...

Hluthafafundur Brims hf. verður haldinn fimmtudaginn 12. desember 2019 í höfuðstöðvum félagsins að Norðurgarði 1, 101 Reykjavík og hefst hann klukkan 17:00. Fundurinn fer fram á íslensku.DagskráTillaga um að staðfesta ákvörðun stjórnar um kaup félagsins á öllu hlutafé í sjávarútvegsfyrirtækjunum, Fiskvinnslunni Kambi hf. og Grábrók ehf.Tillaga frá Útgerðarfélagi Reykjavíkur hf. um að fela stjórn félagsins að leggja fram til samþykktar eða synjunar í síðasta lagi til aðalfundar á árinu 2020, tillögur sem miða að því að auka möguleika erlendra aðila til óbeinnar fjárfestingar í félaginu.Önnur mál.Aðrar upplýsingarÁ hluthafafundum fylgir eitt atkvæði hverri einni krónu í hlutafé.  Eigin bréf félagsins njóta ekki atkvæðisréttar.Atkvæðaseðlar og fundargögn verða afhent á fundarstað.Hluthafar sem ekki eiga kost á að sækja fundinn geta:a) veitt...

Oboya Horticulture Industries AB (“Oboya” or “The Company”) has signed an unconditional framework agreement with Sweden’s first cannabis company Aureum Life AB (“Aureum”) and operates in research, production and sales of medical cannabis. The ambition of the agreement is for Oboya to become a total supplier to Aureum by offering a comprehensive solution for Aureum’s future development of cultivation facilities around the world. The framework agreement does not impose any obligation on orders from Aureum and as a first step in the collaboration, a study will be conducted in which Aureum’s needs will be analyzedAureum and Oboya have discussed a potential collaboration where Aureum uses Oboya as a total supplier for the construction of Aureum’s cultivation facilities around the world....

Oboya Horticulture Industries AB (”Oboya” eller “Bolaget”) har tecknat ett ovillkorat ramavtal med Sveriges första cannabisbolag Aureum Life AB (”Aureum”) med verksamhet inom forskning, produktion och försäljning av medicinsk cannabis. Ambitionen med avtalet är att Oboya blir totalleverantör till Aureum genom att erbjuda en helhetslösning för Aureums kommande uppbyggnationer av odlingsanläggningar runt om i världen. Ramavtalet innebär ingen skyldighet till beställningar från Aureum och som ett första steg i samarbetet ska en studie genomföras där Aureums behov ska analyseras.  Aureum och Oboya har diskuterat ett potentiellt samarbete där Aureum anlitar Oboya som totalleverantör för uppbyggnad av Aureums odlingsanläggningar runt om i världen. Aureum planerar under kommande år att bygga ett antal odlingsanläggningar i världen. Den första...

December 5, 2019AI-based  cancer assessment tools are poised to help pathologists improve speed and accuracy of cancer diagnostics, ultimately leading to better patient careAmsterdam, The Netherlands – Royal Philips ( (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Paige, a leader in computational pathology, announced today a strategic collaboration to deliver clinical-grade AI applications to pathology laboratories. These AI technologies, starting with Paige Prostate, aim to help pathologists identify, quantify and characterize cancer in tissue samples and make precise diagnoses more efficiently. This may, ultimately, positively impact pathologist’s workflow and treatment planning for patients.Pathologists play a crucial role in the detection and diagnosis of a broad range of diseases, including cancer. The increasing...